- Home
- CHPT vs HQL Comparison
CHPT vs HQL Comparison
Compare CHPT & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPT
- HQL
- Stock Information
- Founded
- CHPT 2007
- HQL 1992
- Country
- CHPT United States
- HQL United States
- Employees
- CHPT N/A
- HQL N/A
- Industry
- CHPT Industrial Specialties
- HQL Investment Managers
- Sector
- CHPT Consumer Discretionary
- HQL Finance
- Exchange
- CHPT Nasdaq
- HQL Nasdaq
- Market Cap
- CHPT 321.7M
- HQL 369.6M
- IPO Year
- CHPT N/A
- HQL N/A
- Fundamental
- Price
- CHPT $0.68
- HQL $12.54
- Analyst Decision
- CHPT Hold
- HQL
- Analyst Count
- CHPT 10
- HQL 0
- Target Price
- CHPT $1.46
- HQL N/A
- AVG Volume (30 Days)
- CHPT 20.6M
- HQL 120.9K
- Earning Date
- CHPT 06-04-2025
- HQL 01-01-0001
- Dividend Yield
- CHPT N/A
- HQL 11.56%
- EPS Growth
- CHPT N/A
- HQL N/A
- EPS
- CHPT N/A
- HQL 0.79
- Revenue
- CHPT $407,681,000.00
- HQL N/A
- Revenue This Year
- CHPT $3.54
- HQL N/A
- Revenue Next Year
- CHPT $26.21
- HQL N/A
- P/E Ratio
- CHPT N/A
- HQL $17.08
- Revenue Growth
- CHPT N/A
- HQL N/A
- 52 Week Low
- CHPT $0.51
- HQL $11.34
- 52 Week High
- CHPT $2.44
- HQL $14.37
- Technical
- Relative Strength Index (RSI)
- CHPT 48.12
- HQL 48.60
- Support Level
- CHPT $0.67
- HQL $12.49
- Resistance Level
- CHPT $0.87
- HQL $13.00
- Average True Range (ATR)
- CHPT 0.07
- HQL 0.21
- MACD
- CHPT -0.01
- HQL -0.02
- Stochastic Oscillator
- CHPT 17.11
- HQL 39.69
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.